ANGIOTENSIN II RECEPTOR BLOCKADE IN THE PREVENTION OF INTERSTITIAL EXPANSION

血管紧张素 II 受体阻断预防间质扩张

• 批准号: 7605961
• 负责人: HASSAN N IBRAHIM
• 金额: $ 5.76万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605961
• 关键词: Aldosterone; Angiotensin II Receptor; Angiotensins; Biopsy; Chronic; Chronic rejection of renal transplant; Computer Retrieval of Information on Scientific Projects Database; Development; Disease; Funding; Grant; Injury; Institution; Kidney Diseases; Kidney Transplantation; Losartan; Participant; Patients; Placebo Control; Play; Prevention; Primary Prevention; Randomized; Renin; Renin-Angiotensin-Aldosterone System; Research; Research Personnel; Resources; Role; Source; System; Testing; Transplant Recipients; United States National Institutes of Health; interstitial; kidney allograft; prevent; receptor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The renin angiotensin aldosterone system (RAAS) plays an important role in the progression of renal diseases. Blockade of this system has yielded beneficial results in retarding injury and progression in numerous intrinsic renal diseases. This system, as well as other common mechanisms of progression, operate in chronic allograft nephropathy (CAN). This project will investigate the role of the renin angiotensin aldosterone system (RAAS) in the development of chronic renal allograft nephropathy (CAN). The specific aim is to perform a 5 year randomized placebo controlled primary prevention trial in 150 patients to determine if the angiotensin II receptor blocker, Losartan, can slow or prevent corticol interstitial volume expansion and graft loss from CAN in kidney transplant recipients. The proposed study should provide both pathophysiologic rational and a practical test of therapy in a disease for which there are presently few treatment options. Participants will be admitted to the GCRC for their 5 year exit biopsy.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 肾素-血管紧张素-醛固酮系统(RAAS)在肾脏疾病的发展中起着重要作用。阻断这一系统在延缓许多内源性肾脏疾病的损伤和进展方面产生了有益的结果。该系统和其他常见的进展机制一样，在慢性移植物肾病(CAN)中发挥作用。本项目将探讨肾素-血管紧张素-醛固酮系统(RAAS)在慢性移植肾肾病(CAN)发生发展中的作用。 具体目的是在150名患者中进行为期5年的随机安慰剂对照一级预防试验，以确定血管紧张素II受体阻滞剂氯沙坦是否可以减缓或防止肾移植受者皮质醇间质体积扩张和移植物丢失。这项拟议的研究应该既提供病理生理学上的合理性，也为目前几乎没有治疗选择的疾病的治疗提供实用的测试。参与者将被允许进入GCRC接受为期5年的出境活检。